|Day Low/High||136.96 / 142.27|
|52 Wk Low/High||90.14 / 196.00|
The charts make ZYNE look bearish and not particularly attractive, so avoid.
The way I do that is by using buy-write option strategies.
Five top marijuana stocks and four CBD plays in this speculative space.
You may want to check out GW Pharmaceuticals and Elixinol Global Limited.
In its first report on cannabis companies, Melius says prices are high.
My trading strategy for GWPH whether you are currently long or want to be.
And why I won't recommend any other stocks in these markets, right now.
The main reason most cannabis-related concerns head north to list their shares is banking.
Despite the current stock market, investors are still looking for ways to play the new legalization of hemp.
A potential great pipeline but let's check the charts.
On Wednesday, Canada becomes the first major economy to legalize the recreational use of cannabis.
These stocks offer some diversification or unique features in the legal-weed space.
It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy. As you go down the marijuana rabbit hole, ...
Sales trends and the potential for stronger versions of prescription cannabis offer medical marijuana providers hope.
It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.
The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.
While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.
It's important to know the difference between broken stocks and broken companies.
The game plan is to spot the charts that have more room to run.
Look for this name to jump quickly in popularity in 2018 as investors players search for a convenient way to play the marijuana niche.
Party leaders will have to work toward merging the two versions of tax reform into one final bill.
Growth is almost guaranteed in these two areas, says James McDonald of Index Strategy Advisors.
But the buyers are still unable to produce sustained momentum.
GW Pharma could be the answer to an opiate addiction that isn't understood.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.
TheStreet's Jim Cramer tackled viewer questions on the economy from the NYSE Wednesday. His first viewer question was from Henry Blodget, an investor and CEO of Business Insider.